Mizuho Securities analyst Salim Syed maintained a Buy rating on Cytokinetics (NASDAQ:CYTK) on Sunday, setting a price target of $45, which is approximately 52.44% above the present share price of $29.52.
Syed expects Cytokinetics to post earnings per share (EPS) of -$0.86 for the third quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in Cytokinetics, with an average price target of $45.33.
The analysts price targets range from a high of $58 to a low of $26.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $2.84 million and a net profit of -$54.8 million. The company's market cap is $2.47 billion.
According to TipRanks.com, Mizuho Securities analyst Salim Syed is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.0% and a 48.25% success rate.
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.